These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

178 related articles for article (PubMed ID: 15057650)

  • 21. Breast tumour angiogenesis.
    Fox SB; Generali DG; Harris AL
    Breast Cancer Res; 2007; 9(6):216. PubMed ID: 18190723
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Angiogenesis: an organizing principle for drug discovery?
    Folkman J
    Nat Rev Drug Discov; 2007 Apr; 6(4):273-86. PubMed ID: 17396134
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Judah Folkman.
    Adamis AP; Miller JW
    Semin Ophthalmol; 2009; 24(3):128-9. PubMed ID: 19437346
    [No Abstract]   [Full Text] [Related]  

  • 24. Imaging tumor angiogenesis.
    Red-Horse K; Ferrara N
    J Clin Invest; 2006 Oct; 116(10):2585-7. PubMed ID: 17016553
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The clinical manipulation of angiogenesis: pathology, side-effects, surprises, and opportunities with novel human therapies.
    Thompson WD; Li WW; Maragoudakis M
    J Pathol; 1999 Apr; 187(5):503-10. PubMed ID: 10398113
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Tumor angiogenesis.
    Kerbel RS
    N Engl J Med; 2008 May; 358(19):2039-49. PubMed ID: 18463380
    [No Abstract]   [Full Text] [Related]  

  • 27. Pegaptanib, a targeted anti-VEGF aptamer for ocular vascular disease.
    Ng EW; Shima DT; Calias P; Cunningham ET; Guyer DR; Adamis AP
    Nat Rev Drug Discov; 2006 Feb; 5(2):123-32. PubMed ID: 16518379
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The fight against cancer: the next round.
    Doherty M
    Drug Discov Today; 2004 Nov; 9(22):947-8. PubMed ID: 15539135
    [No Abstract]   [Full Text] [Related]  

  • 29. Anti-Vegf Therapy for Ocular Diseases: Present and Future.
    Campa C; Parodi MB
    Curr Drug Targets; 2020; 21(12):1158. PubMed ID: 32957867
    [No Abstract]   [Full Text] [Related]  

  • 30. Angiogenesis -- SMi conference.
    Foley P
    IDrugs; 2004 Jun; 7(6):551-3. PubMed ID: 15197658
    [No Abstract]   [Full Text] [Related]  

  • 31. Potential future targets for treating ocular neovascularization.
    Barouch FC; Miller JW
    Ophthalmol Clin North Am; 2006 Sep; 19(3):401-9. PubMed ID: 16935215
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Angiogenesis - possibilities, problems and perspectives].
    Kurzyk A
    Postepy Biochem; 2015; 61(1):25-34. PubMed ID: 26281351
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Noninvasive tracer techniques to characterize angiogenesis.
    Haubner R
    Handb Exp Pharmacol; 2008; (185 Pt 2):323-39. PubMed ID: 18626609
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Angiogenesis as a strategic target for ovarian cancer therapy.
    Spannuth WA; Sood AK; Coleman RL
    Nat Clin Pract Oncol; 2008 Apr; 5(4):194-204. PubMed ID: 18268546
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Thrombospondin-1-Based Antiangiogenic Therapy.
    Sims JN; Lawler J
    J Ocul Pharmacol Ther; 2015 Sep; 31(7):366-70. PubMed ID: 26352160
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Basic science of angiogenesis and its progress in clinical application].
    Takakura N
    Rinsho Ketsueki; 2008 Oct; 49(10):1451-9. PubMed ID: 18833929
    [No Abstract]   [Full Text] [Related]  

  • 37. PTK787/ZK 222584, a novel and potent inhibitor of vascular endothelial growth factor receptor tyrosine kinases, impairs vascular endothelial growth factor-induced responses and tumor growth after oral administration.
    Wood JM; Bold G; Buchdunger E; Cozens R; Ferrari S; Frei J; Hofmann F; Mestan J; Mett H; O'Reilly T; Persohn E; Rösel J; Schnell C; Stover D; Theuer A; Towbin H; Wenger F; Woods-Cook K; Menrad A; Siemeister G; Schirner M; Thierauch KH; Schneider MR; Drevs J; Martiny-Baron G; Totzke F
    Cancer Res; 2000 Apr; 60(8):2178-89. PubMed ID: 10786682
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The crucial role of vascular permeability factor/vascular endothelial growth factor in angiogenesis: a historical review.
    Ribatti D
    Br J Haematol; 2005 Feb; 128(3):303-9. PubMed ID: 15667531
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Current insights on the biology and clinical aspects of VEGF regulation.
    Birk DM; Barbato J; Mureebe L; Chaer RA
    Vasc Endovascular Surg; 2008 Dec-2009 Jan; 42(6):517-30. PubMed ID: 18799497
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Diosgenin induces hypoxia-inducible factor-1 activation and angiogenesis through estrogen receptor-related phosphatidylinositol 3-kinase/Akt and p38 mitogen-activated protein kinase pathways in osteoblasts.
    Yen ML; Su JL; Chien CL; Tseng KW; Yang CY; Chen WF; Chang CC; Kuo ML
    Mol Pharmacol; 2005 Oct; 68(4):1061-73. PubMed ID: 15998873
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.